DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug AZD4512 enters human trials
Disease control Recruiting nowThis study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo aims to tame side effects in Tough-to-Treat lymphoma
Disease control Recruiting nowThis study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New 'Two-Pronged' CAR-T attack shows promise for tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new treatment called OriV508 for people with multiple myeloma or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. OriV508 is a type of immunotherapy that uses a virus to deliver instructions to the body to make…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA/HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC